Johnson & Johnson (JNJ) Shares Sold by CAPROCK Group Inc.
CAPROCK Group Inc. decreased its stake in Johnson & Johnson (NYSE:JNJ) by 0.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 42,274 shares of the company’s stock after selling 295 shares during the period. Johnson & Johnson accounts for approximately 1.3% of CAPROCK Group Inc.’s investment portfolio, making the stock its 21st largest position. CAPROCK Group Inc.’s holdings in Johnson & Johnson were worth $5,128,000 as of its most recent filing with the SEC.
Several other hedge funds have also added to or reduced their stakes in JNJ. Allegis Investment Advisors LLC boosted its stake in Johnson & Johnson by 0.5% in the first quarter. Allegis Investment Advisors LLC now owns 9,207 shares of the company’s stock valued at $996,000 after buying an additional 43 shares in the last quarter. Saybrook Capital NC raised its position in shares of Johnson & Johnson by 1.8% in the first quarter. Saybrook Capital NC now owns 53,167 shares of the company’s stock worth $5,753,000 after buying an additional 935 shares during the last quarter. Willingdon Wealth Management purchased a new position in shares of Johnson & Johnson during the first quarter worth approximately $1,774,000. RMB Capital Management LLC raised its position in shares of Johnson & Johnson by 20.9% in the first quarter. RMB Capital Management LLC now owns 5,881 shares of the company’s stock worth $636,000 after buying an additional 1,015 shares during the last quarter. Finally, Rehmann Capital Advisory Group raised its position in shares of Johnson & Johnson by 33.7% in the first quarter. Rehmann Capital Advisory Group now owns 38,606 shares of the company’s stock worth $4,177,000 after buying an additional 9,725 shares during the last quarter. Hedge funds and other institutional investors own 65.35% of the company’s stock.
Johnson & Johnson (NYSE:JNJ) traded down 0.35% during mid-day trading on Friday, hitting $115.36. The stock had a trading volume of 7,717,773 shares. The stock has a market cap of $313.84 billion, a P/E ratio of 20.25 and a beta of 0.75. The firm has a 50-day moving average of $117.08 and a 200-day moving average of $118.16. Johnson & Johnson has a 52-week low of $94.28 and a 52-week high of $126.07.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 18th. The company reported $1.68 EPS for the quarter, beating analysts’ consensus estimates of $1.66 by $0.02. Johnson & Johnson had a return on equity of 25.30% and a net margin of 22.03%. The firm had revenue of $17.80 billion for the quarter, compared to analysts’ expectations of $17.71 billion. During the same period in the prior year, the firm posted $1.49 earnings per share. The firm’s quarterly revenue was up 4.2% on a year-over-year basis. On average, analysts forecast that Johnson & Johnson will post $6.72 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be issued a $0.80 dividend. The ex-dividend date of this dividend is Friday, November 18th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.29. This represents a $3.20 dividend on an annualized basis and a yield of 2.77%. Johnson & Johnson’s dividend payout ratio is currently 56.64%.
A number of equities analysts recently commented on the company. Credit Suisse Group AG reissued a “neutral” rating and set a $123.00 price target on shares of Johnson & Johnson in a research note on Monday, September 19th. Vetr lowered Johnson & Johnson from a “buy” rating to a “hold” rating and set a $119.60 price target for the company. in a research note on Tuesday, November 1st. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 price target for the company in a research note on Friday, August 5th. Jefferies Group increased their price target on Johnson & Johnson from $113.00 to $119.00 and gave the company a “hold” rating in a research note on Thursday, August 4th. Finally, Deutsche Bank AG reissued a “buy” rating and set a $142.00 price target on shares of Johnson & Johnson in a research note on Friday, August 19th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have issued a buy rating to the company’s stock. Johnson & Johnson presently has a consensus rating of “Hold” and a consensus price target of $120.79.
In other Johnson & Johnson news, Director Charles Prince acquired 875 shares of the firm’s stock in a transaction that occurred on Friday, October 21st. The shares were purchased at an average cost of $114.11 per share, for a total transaction of $99,846.25. Following the completion of the acquisition, the director now owns 26,520 shares of the company’s stock, valued at approximately $3,026,197.20. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.11% of the stock is owned by corporate insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.